RU2734774C2 - Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном - Google Patents

Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном Download PDF

Info

Publication number
RU2734774C2
RU2734774C2 RU2017136423A RU2017136423A RU2734774C2 RU 2734774 C2 RU2734774 C2 RU 2734774C2 RU 2017136423 A RU2017136423 A RU 2017136423A RU 2017136423 A RU2017136423 A RU 2017136423A RU 2734774 C2 RU2734774 C2 RU 2734774C2
Authority
RU
Russia
Prior art keywords
diet
chemotherapy
days
subject
fmd
Prior art date
Application number
RU2017136423A
Other languages
English (en)
Russian (ru)
Other versions
RU2017136423A3 (cg-RX-API-DMAC10.html
RU2017136423A (ru
Inventor
Вальтер Д. ЛОНГО
БИАЗЕ Стефано ДИ
Original Assignee
Юниверсити Оф Саутерн Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Саутерн Калифорния filed Critical Юниверсити Оф Саутерн Калифорния
Publication of RU2017136423A publication Critical patent/RU2017136423A/ru
Publication of RU2017136423A3 publication Critical patent/RU2017136423A3/ru
Application granted granted Critical
Publication of RU2734774C2 publication Critical patent/RU2734774C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017136423A 2015-04-16 2016-04-18 Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном RU2734774C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Publications (3)

Publication Number Publication Date
RU2017136423A RU2017136423A (ru) 2019-05-16
RU2017136423A3 RU2017136423A3 (cg-RX-API-DMAC10.html) 2019-09-04
RU2734774C2 true RU2734774C2 (ru) 2020-10-23

Family

ID=57126369

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017136423A RU2734774C2 (ru) 2015-04-16 2016-04-18 Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном

Country Status (14)

Country Link
US (2) US20160303056A1 (cg-RX-API-DMAC10.html)
EP (2) EP4299061A3 (cg-RX-API-DMAC10.html)
JP (2) JP2018511625A (cg-RX-API-DMAC10.html)
KR (1) KR20180002677A (cg-RX-API-DMAC10.html)
CN (1) CN107613979A (cg-RX-API-DMAC10.html)
AU (1) AU2016248443B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017022244A2 (cg-RX-API-DMAC10.html)
CA (2) CA3108664A1 (cg-RX-API-DMAC10.html)
HK (1) HK1249858A1 (cg-RX-API-DMAC10.html)
IL (1) IL255026A0 (cg-RX-API-DMAC10.html)
MX (1) MX2017013133A (cg-RX-API-DMAC10.html)
RU (1) RU2734774C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016168802A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201707710B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022008943A1 (ru) * 2020-07-10 2022-01-13 Елена Анатольевна МАРТЫНОВА Способ проведения курса голодания для тяжелобольных пациентов

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291693A4 (en) * 2015-05-06 2019-04-03 University of Southern California FASTENIMITIER AND IMPROVING DIET FOR THE TREATMENT OF HYPERTENSION AND LIPID DISORDER
JP2019505592A (ja) 2016-02-15 2019-02-28 ユニバーシティ オブ サザン カリフォルニア 糖尿病及び他の疾患を治療するための胚様再生を刺激するための薬剤の組み合わせ及び方法
KR20180136551A (ko) 2016-05-11 2018-12-24 유니버시티 오브 써던 캘리포니아 위장 자가면역/염증 질환을 위한 면역조절 치료로서의 단식 모방 식이(fmd)
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University COMBINATION THERAPY FOR A PI3K-ASSOCIATED DISEASE OR DISORDER
US12628858B2 (en) 2019-03-21 2026-05-19 Cornell University Therapy for colorectal and small intestine cancers
EP3963599B1 (en) 2019-04-30 2026-06-03 University of Southern California Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
JP2023529504A (ja) * 2020-06-14 2023-07-10 エル－ニュートラ・インコーポレイテッド ファスティング状態を維持及び延長する断続的なファスティングバー／ドリンク

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140227373A1 (en) * 2013-02-12 2014-08-14 University Of Southern California Methods and Diets to Protect Against Chemotoxicity and Age Related Illnesses
US20150004280A1 (en) * 2013-07-01 2015-01-01 University Of Southern California Fasting condition as dietary treatment of diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050302A2 (en) * 2009-10-22 2011-04-28 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
AU2011339929B2 (en) * 2010-12-06 2017-05-11 Tom C. Tsang Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
CN106456631A (zh) * 2014-03-06 2017-02-22 南加利福尼亚大学 利用短期饥饿方案结合激酶抑制剂来增强传统化学药物功效和可行性并逆转激酶在正常细胞和组织中的副作用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140227373A1 (en) * 2013-02-12 2014-08-14 University Of Southern California Methods and Diets to Protect Against Chemotoxicity and Age Related Illnesses
US20150004280A1 (en) * 2013-07-01 2015-01-01 University Of Southern California Fasting condition as dietary treatment of diabetes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOSTROM B. et al. Safety and efficacyof metformin for therapy-induced hyperglycemia in children with acute lymphoblasticleukemia // J. Pediatr. Hematol. Oncol., 2013, V.35, pp.504-508. *
BRADY V. et al. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy // Diabetes Technol. Ther., 2014, V.16, pp.874-879. *
BRADY V. et al. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy // Diabetes Technol. Ther., 2014, V.16, pp.874-879. BOSTROM B. et al. Safety and efficacy of metformin for therapy-induced hyperglycemia in children with acute lymphoblastic leukemia // J. Pediatr. Hematol. Oncol., 2013, V.35, pp.504-508. CHERYL A.K. et al. Controlling Hyperglycemia as an Adjunct to Cancer Therapy // INTEGRATIVE CANCER THERAPIES, 2005, V.4, pp.25-31. *
CHERYL A.K. et al.Controlling Hyperglycemia as an Adjunct to Cancer Therapy // INTEGRATIVE CANCER THERAPIES,2005, V.4, pp.25-31. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022008943A1 (ru) * 2020-07-10 2022-01-13 Елена Анатольевна МАРТЫНОВА Способ проведения курса голодания для тяжелобольных пациентов

Also Published As

Publication number Publication date
RU2017136423A3 (cg-RX-API-DMAC10.html) 2019-09-04
CN107613979A (zh) 2018-01-19
EP4299061A2 (en) 2024-01-03
US20210137856A1 (en) 2021-05-13
EP4299061A3 (en) 2024-02-28
AU2016248443B2 (en) 2021-03-18
JP2021008491A (ja) 2021-01-28
IL255026A0 (en) 2017-12-31
ZA201707710B (en) 2019-04-24
EP3283073A2 (en) 2018-02-21
BR112017022244A2 (pt) 2018-07-10
JP2018511625A (ja) 2018-04-26
HK1249858A1 (zh) 2018-11-16
KR20180002677A (ko) 2018-01-08
CA2982875A1 (en) 2016-10-20
AU2016248443A1 (en) 2017-11-02
EP3283073A4 (en) 2019-02-13
WO2016168802A2 (en) 2016-10-20
CA3108664A1 (en) 2016-10-20
CA2982875C (en) 2021-10-19
RU2017136423A (ru) 2019-05-16
US20160303056A1 (en) 2016-10-20
MX2017013133A (es) 2018-09-07

Similar Documents

Publication Publication Date Title
US20210137856A1 (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
AU2020200297B2 (en) Methods and diets to protect against chemotoxicity and age related illnesses
KR102811762B1 (ko) 상승된 콜레스테롤 수준 및/또는 상승된 ldl 수준의 감소용 금식 모방 규정식 조성물
JP2021183622A (ja) 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
HK40100962A (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
US12285453B2 (en) Fasting-mimicking diet promotes cancer-free survival in acute lymphoblastic leukemia models